Combined analysis of the expression SDHs and IPS score proved that COAD patients with high SDHA expression are more suitable for immunotherapy such as anti-PD-1/PD-L1 (p = 3.4×10-7) and anti-CTLA-4 (p = 5.6×10-6) treatment (Figures 7D, E, Table S14). The gene discussed is SDHA; the disease is colon adenocarcinoma.